Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors.

Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors. Breast Cancer Res. 2020 06 23; 22(1):69.

View in: PubMed

subject areas

Antineoplastic Combined Chemotherapy Protocols
B7-H1 Antigen
Breast Neoplasms
Carcinoma, Ductal, Breast
Carcinoma, Lobular
Combined Modality Therapy
Drug Approval
Female
Follow-Up Studies
Humans
Immunohistochemistry
Lymphocytes, Tumor-Infiltrating
Middle Aged
Prognosis
Retrospective Studies
Survival Rate
United States
United States Food and Drug Administration

authors with profiles

MICHAEL GILCREASE
ERIKA RESETKOVA
LEI HUO
STACY MOULDER
MING ZHAO